Inspire Medical upgraded to Overweight from Equal Weight at Wells Fargo

Wells Fargo upgraded Inspire Medical (INSP) to Overweight from Equal Weight with a price target of $90, down from $101. The company reported a “clean” Q3 report and reset its 2026 outlook, the analyst tells investors in a research note. Wells says its recent obstructive sleep apnea survey supports Inspire’s new 2026 outlook. It sees a positive risk/reward at current share levels. Inspire’s lowered 2026 revenue growth expectations brings a “clearing event,” according to Wells.